Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Teva
Dow
UBS
Julphar
Deloitte
Boehringer Ingelheim
Baxter
AstraZeneca

Generated: December 15, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

« Back to Dashboard

Clinical Trials for Nicardipine Hydrochloride In 0.9% Sodium Chloride

Trial ID Title Status Sponsor Phase Summary
NCT00007592 Hypertension Screening and Treatment Program Completed VA Office of Research and Development N/A Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00093925 Clevidipine in the Postoperative Treatment of Hypertension (ECLIPSE-NIC) Completed The Medicines Company Phase 3 The purpose of this study is to establish the safety of clevidipine in the treatment of postoperative hypertension. Approximately 250-500 patients with postoperative hypertension after undergoing coronary artery bypass grafting (CABG), off-pump coronary artery bypass (OPCAB) or minimally invasive direct coronary artery bypass (MIDCAB) surgery and/or valve replacement/repair procedures were anticipated to be randomly assigned to one of two treatment groups: clevidipine or nicardipine.
NCT00137501 Two Dose Regimens of Nifedipine for the Management of Preterm Labor Terminated American University of Beirut Medical Center Phase 3 Preterm birth is one of the most important causes of perinatal morbidity and mortality worldwide. Prevention and treatment of preterm labor is important, not as an end in itself, but as a means of reducing adverse events for the neonate. A wide range of tocolytics, drugs used to suppress uterine contractions, have been tried. Magnesium sulfate (MgSO4) is the most widely used tocolytic at the American University of Beirut Medical Center despite the fact that an effective tocolytic role of MgSO4 has never been established. Moreover, the currently available data are suggestive of deleterious fetal effects of MgSO4 in the setting of preterm labor to the extent that some authorities are recommending abandoning it for routine use as a tocolytic therapy. Calcium channel blockers have the ability to inhibit contractility in smooth muscle cells. Consequently, nifedipine has emerged as an effective and rather safe alternative tocolytic agent for the management of preterm labor after several studies have shown that the use of nifedipine in comparison with other tocolytics is associated with a more frequent successful prolongation of pregnancy, resulting in significantly fewer admissions of newborns to the neonatal intensive care unit, and is associated with a lower incidence of respiratory distress syndrome. The unequivocal impact of this method of tocolysis on short term postponement of delivery and the opportunity that this provides for affecting in-utero transfer and steroid administration has prompted many investigators to recommend focusing future trials on testing different dose regimens of nifedipine. To the best of the investigators' knowledge, no study comparing two different dose regimens of nifedipine has been previously published in the literature. The objective of their study is to compare the effectiveness of a high versus a low dose regimen in a total of 200 patients admitted with the diagnosis of preterm labor between 24 and 34 weeks of gestation. In addition, the investigators' study will try to assess the safety profile of the 2 dose regimens on the mother and the neonate by assessing a selected number of outcome variables. The data generated will be used to change their protocol for managing patients presenting with threatened preterm delivery and will fill the existing gap regarding the most effective and safest dose regimen of nifedipine in such patients.
NCT00226096 Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Completed National Health and Medical Research Council, Australia N/A The purpose of the study is to determine whether lowering high blood pressure levels after the start of a stroke caused by bleeding in the brain (intracerebral haemorrhage) will reduce the chances of a person dying or surviving with a long term disability. The study will be undertaken in two phases: a vanguard phase in 400 patients, to plan for a main phase in 2000 patients.
NCT00226096 Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Completed The George Institute N/A The purpose of the study is to determine whether lowering high blood pressure levels after the start of a stroke caused by bleeding in the brain (intracerebral haemorrhage) will reduce the chances of a person dying or surviving with a long term disability. The study will be undertaken in two phases: a vanguard phase in 400 patients, to plan for a main phase in 2000 patients.
NCT00325793 IV Double and Triple Concentrated Nicardipine for Stroke and ICH Unknown status PDL BioPharma, Inc. Phase 4 Hypertension (high blood pressure) can often cause neurological worsening in patients with stroke, intracerebral hemorrhage and subarachnoid hemorrhage. Intravenous infusion of nicardipine (Cardene) for control of hypertension is FDA approved. The disadvantage of Nicardipine IV drip is the relative large volume of fluid needed (up to 150 cc/hr). The purpose of this study is to evaluate safety and efficacy of double or triple concentrated peripheral intravenous (IV) Nicardipine.
NCT00325793 IV Double and Triple Concentrated Nicardipine for Stroke and ICH Unknown status OSF Healthcare System Phase 4 Hypertension (high blood pressure) can often cause neurological worsening in patients with stroke, intracerebral hemorrhage and subarachnoid hemorrhage. Intravenous infusion of nicardipine (Cardene) for control of hypertension is FDA approved. The disadvantage of Nicardipine IV drip is the relative large volume of fluid needed (up to 150 cc/hr). The purpose of this study is to evaluate safety and efficacy of double or triple concentrated peripheral intravenous (IV) Nicardipine.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Nicardipine Hydrochloride In 0.9% Sodium Chloride

Condition Name

Condition Name for Nicardipine Hydrochloride In 0.9% Sodium Chloride
Intervention Trials
Hypertension 8
Subarachnoid Hemorrhage 3
Intracerebral Hemorrhage 3
Cerebral Vasospasm 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Nicardipine Hydrochloride In 0.9% Sodium Chloride
Intervention Trials
Hypertension 11
Hemorrhage 7
Cerebral Hemorrhage 6
Aneurysm 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Nicardipine Hydrochloride In 0.9% Sodium Chloride

Trials by Country

Trials by Country for Nicardipine Hydrochloride In 0.9% Sodium Chloride
Location Trials
United States 88
China 11
Japan 5
Australia 5
France 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Nicardipine Hydrochloride In 0.9% Sodium Chloride
Location Trials
New York 6
Illinois 6
Ohio 5
Pennsylvania 4
California 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Nicardipine Hydrochloride In 0.9% Sodium Chloride

Clinical Trial Phase

Clinical Trial Phase for Nicardipine Hydrochloride In 0.9% Sodium Chloride
Clinical Trial Phase Trials
Phase 4 11
Phase 3 8
Phase 2 3
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Nicardipine Hydrochloride In 0.9% Sodium Chloride
Clinical Trial Phase Trials
Completed 15
Recruiting 8
Unknown status 6
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Nicardipine Hydrochloride In 0.9% Sodium Chloride

Sponsor Name

Sponsor Name for Nicardipine Hydrochloride In 0.9% Sodium Chloride
Sponsor Trials
The Medicines Company 4
Yonsei University 3
University of Minnesota - Clinical and Translational Science Institute 2
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Nicardipine Hydrochloride In 0.9% Sodium Chloride
Sponsor Trials
Other 63
Industry 8
NIH 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
QuintilesIMS
Queensland Health
Federal Trade Commission
Farmers Insurance
Daiichi Sankyo
Fuji
AstraZeneca
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.